BACKGROUND: Indications for and delivery of adjuvant therapies for pediatric nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) have been derived largely from adult studies; therefore, significant concern remains regarding radiation exposure to normal tissue. The authors report long-term treatment outcomes and toxicities for pediatric and young adult patients with high-grade NRSTS who were treated on a prospective trial using limited-margin radiotherapy. METHODS: Sixty-two patients (ages 3-22 years) with predominantly high-grade NRSTS requiring radiation were treated on a phase 2 institutional study of conformal external-beam radiotherapy and/or brachytherapy using a 1.5-cm to 2-cm anatomically constrained margin. The estimated cumulative incidence of local failure, Gray's method estimated cumulative incidence of local failure, Kaplan-Meier method estimated survival, competing-risk regression model determined predictors of disease outcome, and toxicity was reported according to CTCAE v2.0. RESULTS: At a median followup of 5.1 years (range, 0.2-10.9 years), 9 patients had experienced local failure. The 5-year overall cumulative incidence of local failure was 14.8% (95% confidence interval [CI], 7.2%-25%), and all but 1 local failure occurred outside the highest-dose irradiation volume.
INTRODUCTION
Soft tissue sarcomas (STS) are a group of rare tumors, with an estimated 12,310 new cases representing 0.7% of all new cancers in the United States in 2016. 1 Despite an overall scarce incidence, STS are disproportionally represented in the pediatric patient population, comprising about 7% of all childhood cancers. 2 Nonrhabdomyosarcoma STS (NRSTS) represent roughly one-half of these pediatric cases, with approximately 500 to 550 children and adolescents diagnosed annually. 2, 3 Important differences unique to pediatric and young adult NRSTS include a bimodal incidence distribution 4, 5 and distinct histologic subtypes. 3, 6 Limited numbers of prospective clinical trials specific to pediatric NRSTS have been conducted, [7] [8] [9] [10] and indications and techniques of adjuvant therapies have been derived largely from adult studies. However, concern regarding long-term treatment-related morbidity remains, particularly related to normal tissue radiation exposure. Although radiation dose has been historically more limited in the pediatric setting, the irradiated tissue volume in the 3 reported prospective clinical trials within the United States devoted specifically to pediatric NRSTS has mirrored historic adult approaches. [8] [9] [10] Thus, STS irradiation volumes beyond the gross tumor or resection bed in both adult and pediatric patients have historically ranged from 4 to 6 cm in the longitudinal plane and from 1.5 to 3 cm in the radial plane. [8] [9] [10] [11] [12] It is noteworthy that toxicity related to local control therapies was essentially unreported in those early pediatric studies.
In an effort to minimize normal tissue exposure while maintaining critical local tumor control in pediatric and young adult patients with high-grade NRSTS, we designed a prospective trial to test the efficacy and tolerability of focal, limited-margin radiation therapy (RT). We report the long-term outcomes from that study, detailing disease control, patterns of disease failure, predictors of local failure (LF) and survival, pathologic and imagingbased responses to neoadjuvant therapy, survival outcomes, and acute and late toxicity.
MATERIALS AND METHODS
From March 2003 to June 2013, 62 patients aged 25 years and younger with NRSTS were enrolled on an institutional review board-approved, participant-consented, prospective phase 2 clinical trial of limited-margin RT in the management of pediatric and young adult musculoskeletal tumors. 13 NRSTS was restricted to tumors within the STS section of the American Joint Committee on Cancer's AJCC Cancer Staging Manual, seventh edition, 14 with the exception of fibromatosis, which was excluded. Tumor grade was assessed by the Pediatric Oncology Group 15 classification system, with grade 1 and 2 tumors considered low grade and grade 3 tumors considered high grade. Tumor stage was based on the AJCC Cancer Staging Manual, seventh edition. 14 The degree of surgical resection was classified based on the description by Enneking, 16 and surgical margin status was based on pathologic assessment and was defined as positive with tumor on inked margins. Indications for primary-site RT included the presence of high-grade sarcoma, positive microscopic margins, limited resectability, or locally recurrent nonirradiated sarcoma. Chemotherapy was primarily restricted to patients who had large (>5 cm), high-grade tumors.
RT delivery and protocol follow-up have been described previously. 17, 18 Target volumes were delineated based on co-registration of computed tomography and magnetic resonance imaging treatment-planning data sets obtained in the treatment position. The gross tumor volume (GTV) encompassed the postoperative surgical bed or gross tumor and was restricted along fascial planes and adjacent bone. An anatomically constrained, 2.0-cm clinical target volume (CTV) was added to the GTV without specific targeting of incisions or drain sites. In 2006, with the opening of the Children's Oncology Group ARST0332 clinical trial, the CTV was modified to a 1.5-cm margin in an effort to further reduce treatment volumes. With the inclusion of potentially operable, highrisk patients within the neoadjuvant treatment arm of ARST0332, neoadjuvant therapy was used more frequently after 2006. A patient-specific planning target volume (PTV) that ranged from 0.4 to 1.0 cm was added to the CTV for external-beam RT. Protocol-specified RT doses ranged from 45 to 50 grays (Gy) preoperatively, from 55.8 to 63 Gy postoperatively, and from 64.8 to 70.2 Gy definitively and were delivered in 1.8-Gy daily fractions. If patients had positive/close surgical margins, then postoperative boost RT was delivered at a median dose of 14.3 Gy (range, 9-23.8 Gy). RT dose guideline deviations were made based on the protection of adjacent normal tissue at the discretion of the treating radiation oncologist or as a result of disease progression.
Treatment-related toxicity was assessed weekly during RT and at each follow-up visit according to the National Institutes of Health Common Toxicity Criteria for Adverse Events, version 2.0 (available at: http://ctep. info.nih.gov/reporting/ctc.html) and was defined as early (within 3 months from the start of RT) or late (beyond 3 months after the start of RT). Treatment failure was defined as LF (within the anatomic primary tumor site) or distant failure (DF) (distinct from the primary site) based on imaging or pathology. LF failure was further classified based on recurrent tumor volume and associated RT dosimetry. 19 Patients were taken off protocol at the time of recurrence or other defined events (see below), or 10 years after protocol enrollment, or at age 18 years, whichever occurred later.
The cumulative incidence (CIN) of LF, DF, and late grade 3 or higher toxicity was estimated using the competing-risks method and was compared using the Gray test. 20 Competing risks included developing DF, a subsequent malignant neoplasm, or death from any cause. Patients who either had recurrent disease or died within 3 months of the end of RT were not included in the analysis of late toxicity. Event-free survival (EFS) was defined as the time to any event, including LF, DF, a subsequent malignant neoplasm, or death, whichever occurred first. Overall survival (OS) was defined as time to death from any cause. Probability estimates of EFS and OS with 95% confidence intervals (CIs) were calculated using the Kaplan-Meier method and were compared using the log-rank test. A regression model for competing risks proposed by Fine and Gray 21 was used to identify independent predictors of LF, and a Cox proportional hazards model was used to identify predictors of EFS and OS. Variables with P < .1 in univariate analysis were further Original Article analyzed in multivariate analysis, and highly correlated or incomplete variables were not included in the multivariate analysis. The effect of variables without LF failure events could not be computed reliably, and these variables were excluded from the analysis. Risk estimates, expressed as hazards ratios (HRs) and 95% CIs, were reported. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). A 2-sided significance level of P < .05 was considered statistically significant.
RESULTS

Patient and Treatment Characteristics
In total, 62 patients with high-grade or locally recurrent, nonirradiated NRSTS were enrolled from March 2003 to June 2013. Baseline characteristics of our study population are summarized in Table 1 . The median duration of follow-up was 5.1 years (range, 0.2-10.9 years) for all patients and 6.1 years (range, 2.1-10.9 years) for patients who remained on study at the time of analysis. The majority of patients underwent surgical resection followed by adjuvant RT (44 patients; 71%), whereas neoadjuvant chemoradiotherapy was received by 12 patients (19%), of whom 6 received postoperative RT for positive/close surgical margins. Six patients (10%) who had inoperable disease received definitive-intent RT. Of the patients who received external-beam photon irradiation, 38 (61%) received 3-dimensional conformal RT, 19 (31%) received intensity-modulated RT, and 5 (8%) received both modalities. Brachytherapy was received by 22 patients (35%), including 12 (19%) who were treated in conjunction with external-beam RT and 10 (16%) who received brachytherapy alone. Twenty-six patients (42%) underwent wide local excision, and 30 (48%) underwent intralesional or marginal excision. Thirty-five patients (56%) received chemotherapy as part of study therapy.
Patterns of Treatment Failure and Predictors of LF
Supporting Table 1 summarizes the clinical outcomes for the entire cohort and for those patients who were without metastasis at study enrollment (see online supporting information). Local recurrence developed in 9 patients, including 1 patient with synchronous local and distant recurrences. The median time to LF was 9.2 months (range, 1-38 months) from the date of study enrollment. The estimated CIN of LF with a competing risk at 5 years for the entire cohort was 14.8% (95% CI, 7.2%-25%) (Fig. 1A) . The CIN of LF at 5 years was 11% (95% CI, 4.4%-21.1%) in patients who underwent resection, and the CIN at 1 year was 33% (95% CI, 1.9%-73.7%) in those who received definitive RT (Gray test; P < .001) (Supporting Fig. 1A ; see online supporting information). No LFs were observed in patients who underwent complete surgical resection with negative microscopic margins, whereas the CIN of LF at 5 years was 20.8% (95% CI, 8.2%-37.4%) in patients who had positive surgical margins (P 5 .016) (Fig. 1B) . Similarly, no LF was observed in patients who received neoadjuvant chemoradiation, whereas a 5-year estimated CIN of LF of 14.3% (95% CI, 5.7-26.7%) was observed in patients who received adjuvant chemoradiation (P 5 .172) (Supporting Fig. 1B ; see online supporting information).
In an effort to better define LF patterns, recurrent volumes were delineated on co-registered failure and simulation imaging with associated dosimetry. Recurrences were then further classified as central (>95% of consensus recurrence volume within the 95% isodose), in-field (80%-95% within the 95% isodose), marginal (20%-80% within the 95% isodose), or outside (<20% within the 95% isodose), and the volume of overlap of the recurrent volume and initial GTV and CTV was determined. 19 In all but 1 patient, the LF appeared to be a central failure; this was a patient who had recurrent synovial sarcoma of the wrist at the time of study enrollment and received adjuvant brachytherapy alone. Evaluation of the extent of overlap with recurrent volume and initial CTV volume demonstrated >90% overlap with the CTV in all patients with the exception of the 1 patient described above. The clinical and dosimetric characteristics of the patients who experienced a local recurrence alone or local and distant recurrences are detailed in Table 2. A regression model for competing risks was used to identify independent significant predictors of LF within the overall patient cohort among various patient and clinicopathologic variables (Table 3) . On univariate analysis, the factors identified as significant included younger age at study enrollment (P 5 .002), extent of resection (P 5 .091), recurrent disease (P 5 .066), and receipt of definitive RT (P 5 .023). On multivariate analysis, only younger age was significantly associated with an increased risk of LF (P 5 .004).
In total, 19 patients developed isolated new or progressive distant metastatic disease as the first evidence of disease progression. Ten of these patients were nonmetastatic at study enrollment, and the predominant distant sites of metastasis for these patients were lung (n 5 6), lymph nodes (n 5 2), soft tissue (n 5 1), and bone (n 5 1). The estimated 5-year CIN of DF for the entire cohort was 30.9% (95% CI, 19.7%-42.7%) (Supporting Fig. 2 ; see online supporting information).
Neoadjuvant Chemoradiation: Pathologic and Positron-Emission Tomography Response
Twelve patients received neoadjuvant chemoradiation, all with ifosfamide-doxorubicin-based chemotherapy. Pathologic response at the time of definitive surgical resection was correlated with fluorodeoxyglucose-positron emission tomography response in the 7 patients who completed a pretherapy and presurgical scan. Within the limitations of this small study cohort, there was no clear correlation between the percentage necrosis and the percentage change in tumor maximum standardized uptake value after neoadjuvant chemoradiotherapy, yet formal statistical analysis was not possible given limited sample size. The pathologic and positron-emission tomography responses and the additional clinical and treatment characteristics of these patients are detailed in Supporting Table 2 (see online supporting information). 
Survival Outcomes
Kaplan-Meier estimates of EFS and OS at 5 years were 49.3% (95% CI, 36.3%-61.1%) and 67.9% (95% CI, 54.2%-78.3%), respectively (Fig. 2) . Twenty-one patients have died, 19 of progressive NRSTS and 2 of unknown causes. Six of 9 patients who experienced LF with or without DF died of their disease, whereas 12 of 18 patients with isolated DF died of their disease. Patients who had metastatic disease at the time of diagnosis had significantly reduced 5-year EFS and OS compared with patients who did not have metastatic disease (both P < .0001) (Fig. 2) . A multivariate Cox regression model identified metastasis at study enrollment as the only significant predictor of EFS (HR, 1.78; 95% CI, 2.04-17.11; P 5 .001) and OS (HR, 1.97; 95% CI, 2.12-24.13; P 5 .002) ( Table 4 ).
Acute and Late Toxicities
On the basis of prospective toxicity evaluation and scoring of the maximal toxicity for each toxicity type, there were 7 acute (within 3 months from the start of RT) grade 3 or 4 radiation-related toxicity events observed in 6 patients (Supporting Table 3 ; see online supporting information). These were related largely to RT dermatitis and associated pain, and all but 1 patient had resolution within the 3-month time frame. Seventeen late grade 3 or 4 radiationrelated events were observed in 13 patients, including 3 patients who experienced > 1 event. Most late events were attributed to skin and subcutaneous tissue toxicity. Two patients experienced bone fracture, and several patients experienced late effects potentially associated with RT, including small bowel obstruction and brain necrosis. Three patients experienced wound complications, including 2 who received neoadjuvant chemoradiotherapy. One patient required an amputation secondary to nonhealing wound complications after adjuvant RT. The 5-year CIN of late grade 3 or 4 toxicity for the entire cohort was 15% (95% CI, 7.2%-25.3%) (Fig. 3) .
Three patients developed subsequent malignant neoplasms. Two patients, both who were treated initially with adjuvant chemoradiation, developed myelodysplastic syndrome 1.1 and 1.5 years after the end of primary therapy, respectively. One patient who received adjuvant RT developed an orbital embryonal rhabdomyosarcoma within the previously irradiated field 1.2 years after completing primary therapy. At last follow-up, 2 patients remained alive without signs of malignancy, and 1 patient died of progressive acute myeloid leukemia. Although significant challenges exist in attributing the receipt of specific treatments to second cancers, RT would appear to be a less likely culprit in the development of myelodysplastic syndrome in these 2 patients, and its role in the subsequent development of orbital rhabdomyosarcoma is unclear given the very short interval from primary therapy.
DISCUSSION
Findings from this prospective study demonstrate a high rate of local tumor control through the delivery of limited-margin RT using conformal external-beam RT or Abbreviations: 3DCRT, 3-dimensional conformal radiation therapy; AJCC, American Joint Committee on Cancer; CI, confidence interval; EBRT, external-beam radiation therapy; HR, hazard ratio; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified; RT, radiation therapy; SE, standard error. a This P value indicates a statistically significant difference. b The univariate analysis of extent of resection and treatment intent result in P <.1 but are based on a subset of the data; therefore, these variables were not included in the multivariate model. brachytherapy, with an overall CIN of LF for high-grade pediatric and young adult NRSTS of 15% at 5 years and a lack of failures in those patients who underwent margin-negative resection. It is noteworthy that this appears to have been accomplished without an increased incidence of marginal failures, with all but 1 patient with a local recurrence within the highest-dose irradiated volume. Treatment-related morbidity appears to be acceptable with this approach, with an estimated CIN of late grade 3 or higher toxicity of 15%. In this high-risk cohort (54.8% of patients with grade 3 tumors > 5 cm), as expected, over one-half of patients developed DF, with estimated 5-year EFS and OS rates of 49% and 68%, respectively. Through the collaborative efforts of the Pediatric Oncology Group and the Children's Oncology Group, 3 prospective clinical trials devoted to pediatric and young adult NRSTS have been reported. [8] [9] [10] In those studies, which ran from 1986 to 2000, the irradiated volume was defined as the original tumor volume at the time of diagnosis, including any subsequent surgical manipulation, with an additional 5-cm margin in all directions. On the basis of data demonstrating a correlation with the extent of irradiated volume and subsequent toxicity incidence and severity in adult patients with STS, 11, 22, 23 in 2003, we prospectively implemented a significant volumereduction approach to the management of pediatric NRSTS with reduced target margins of 2 cm without the specific incorporation of areas of prior surgical intervention. This was facilitated in part through an additional advancement within the trial with the systematic incorporation of image fusion, facilitating the co-registration of presurgery and pre-RT imaging, including magnetic resonance imaging and positron-emission tomography to substantially assist in target delineation. With the primary study objectives of the initial collaborative studies focused on the role of adjuvant and definitive chemotherapy, local control estimates and late musculoskeletal toxicity were underreported. Thus, our prospective, mature, local control and long-term toxicity assessment with modern RT techniques using limited margin serves as an important benchmark in disease-related and therapy-related outcomes for pediatric and young adult patients with NRSTS. Of note, a volume-reduction approach in neoadjuvant RT using a longitudinal, 3-cm CTV margin for intermediate-grade to high-grade tumors 8 cm and a 2-cm CTV margin for other tumors has produced significant reductions in treatment-related morbidity and stable local control rates relative to historic controls among adult patients with extremity STS. 24 While we await long-term results, initial findings from the randomized VORTEX trial (clinicaltrials.gov identifier NCT00423618), which compared a 5-cm longitudinal margin from the GTV in the standard arm to a 2-cm margin in the experimental arm among adult patients with extremity STS who received adjuvant RT, also do not suggest increased LF with limited-margin adjuvant RT. 25 Since the initiation of this trial, 2 international prospective clinical trials of pediatric and young adult patients with NRSTS have been completed: the Children's Oncology Group ARST0332 trial and the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) NRSTS 2005 trial. 7, [26] [27] [28] Both of these trials incorporated reduced-margin RT, with the CTV ranging from 1 to 2 cm and the inclusion of sites of surgical manipulation. While we await the long-term results of ARST0332, initial results published in abstract form indicate an estimated 3-year EFS rate similar to or slightly better than historic control rates, with 91% in the surgery alone cohort, 79% in the adjuvant RT cohort, 68% in the adjuvant chemo-RT cohort, and 52% in the neoadjuvant/ definitive chemo-RT cohort. 28 Results from the EpSSGled synovial sarcoma clinical trial were recently reported, with an estimated 3-year EFS rate in low-risk, intermediate-risk, and high risk patients of 92%, 91%, and 78%, respectively. Although no definitive conclusions can be made regarding the role of RT given investigator discretion regarding the administration of RT in intermediate-risk patients, as the authors point out, only 2 of 24 low-risk patients who underwent surgery alone recurred, and there were no local relapses in the 13 patients who underwent complete resection of T2 tumors that were managed with surgery and chemotherapy alone. Within the limitations of disparate classification and treatment schemes as well as differing disease control endpoints, long-term local control and EFS within our cohort were is in keeping with these recent reports.
Prognostic factors for local control within pediatric NRSTS remain incompletely defined and are drawn largely from relatively small, single-institution, retrospective studies. Extent of surgical resection, histologic grade, tumor size, primary site, and microscopic residual disease have been implicated in several studies. [29] [30] [31] In patients with initially unresectable disease, reported factors associated with increased LF include female sex, age older than 10 years, MPNST histology, and lower doses of RT. 29, 30 It is noteworthy that young age was associated with increased LF in our cohort. Although treatment de-escalation may be posited, review of patients aged 6 years or younger with LF revealed no clear clinicopathologic or treatment-related variables to account for this observation ( Table 2) . Enrollment of large cohorts of pediatric patients with NRSTS on the ARST0332 and EpSGG 2005 trials, as well as the ongoing ARST1321 trial, will likely provide additional information related to this important question. With the emphasis of neoadjuvant RT and restriction to extremity and trunk STS, findings from ARST1321, however, may be less generalizable across pediatric NRSTS tumor sites and RT approaches.
In the current study, surgical margin status significantly influenced LF, with a 5-year CIN of 20.8% in patients who underwent marginal resection, a finding supported in other pediatric NRSTS series 31, 32 and in the adult STS setting. 33 Thus, high-grade pediatric and young adult patients with margin-positive NRSTS appear to represent a high-risk group. Reasons for this are likely multifactorial, including tumor-related factors (anatomic site and histologic type) and RT-related factors (adequate doses or large enough target margins in the postoperative setting). Given similar rates of LF observed in the margin-positive patients in our cohort who were treated with limited target margins and patients in other studies who were treated with larger target margins, 31, 32 as well as our dosimetric analysis of LF, currently used target margins would not appear to contribute significantly. However, in light of the critical impact of adjuvant RT doses beyond 64 Gy in patients with positive surgical margins on both tumor control and survival outcomes in adult patients, 34 the adjuvant RT doses used on this protocol (range, 52.2-64.8 Gy) may be inadequate in the face of microscopic residual disease. Although the role of boost-dose RT for patients with close/positive margins after neoadjuvant radiation is controversial, 35, 36 LFs were not observed in patients who received neoadjuvant chemoradiation, one-half of whom received postoperative boost RT as a result of margin status. Potential therapeutic interventions to mitigate this elevated LF risk in patients with positive margins thus may include RT dose escalation, as demonstrated in pediatric patients with Ewing sarcoma. 37 The incorporation of systemic, putative radiosensitizers, as currently studied in the ARST1321 trial, offers an additional line of investigation that may specifically benefit these high-risk patients.
Finally, although long-term, significant, treatmentrelated toxicity appears to be manageable at 15% at 5 years, it still represents a significant morbidity to bear in a population expected to continue to age and develop. 38 To address long-term toxicity, refined indications for adjuvant RT within ARST0322 included the omission of RT for all low-grade tumors and for T1, high-grade tumors with negative margins 28 ; whereas adjuvant RT was omitted in all margin-negative patients with synovial sarcoma regardless of tumor size in the EpSSG NRSTS 2005 trial, resulting in 3 of 37 patients with LF or locoregional failure at 3 years. 7 The absence of LF in patients with negative margins in our study, including 7 patients who had high-grade T2 tumors, also argues for considering the omission of RT in patients with completely resected, high-grade tumors regardless of tumor size. With the omission of RT in these patients, 4 late grade 3 or higher toxicities in 3 patients would have been avoided. Further considerations for subsequent studies in this population may also include more restricted RT delivery by targeting only area(s) of microscopic residual disease, 39 and the incorporation of proton-beam RT 40 to further reduce normal tissue exposure.
